Modafinil, Sleep Architecture and Cocaine Relapse
Information source: Yale University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine Dependence
Intervention: Modafinil (Drug); Cognitive Behavioral Therapy (Behavioral)
Phase: Phase 2
Status: Recruiting
Sponsored by: Yale University Official(s) and/or principal investigator(s): Peter Morgan, MD, PhD, Principal Investigator, Affiliation: Yale University
Overall contact: Erica Forselius, B.A., Phone: 203-974-7545, Email: erica.forselius@yale.edu
Summary
The medication modafinil has been shown to reduce cocaine use in some cocaine users. The
investigators have shown that modafinil taken in the morning improves sleep in chronic
cocaine users. The investigators hypothesize that the beneficial effects of modafinil in
reducing cocaine use may be related to specific effects modafinil has on sleep. This study
will measure sleep and cocaine use in cocaine dependent persons who are trying to stop using
cocaine, and will test the connection between modafinil's effects on sleep and cocaine use.
Clinical Details
Official title: Modafinil, Sleep Architecture and Cocaine Relapse
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Number of cocaine-free urines
Secondary outcome: Polysomnographically measured sleep
Eligibility
Minimum age: 25 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 25-50 years of age;
- voluntary, written, informed consent;
- seeking but not currently enrolled in treatment for cocaine use;
- self-reported, current use of cocaine by smoked or intravenous route at least one
time each week in the past month, with ≥1g used within a single 24-hour period and
≥3g used in the month;
- positive urine test for cocaine (benzoylecognine) at the time of screening and study
start
- dependence on cocaine in the past year as measured by a score ≥ 3 on the Severity of
Dependence Scale(Kaye and Darke, 2002);
- chronic use in the past year as determined by self-reported use in at least 9 of the
past 12 months;
- lifetime diagnosis of cocaine dependence with a duration of at least 2 years as
determined by the Structured Clinical Interview for DSM-IV (SCID).
Exclusion Criteria:
- evidence of any neurological condition or a chronic medical condition including
diabetes, cardiovascular disease or history of cardiac problems, HIV-seropositivity,
liver disease, hypertension, asthma requiring daily medication, dementia, movement
disorder, history of head trauma with loss of consciousness, sleep apnea, narcolepsy,
restless leg syndrome, periodic limb movement disorder, REM sleep disorder,
pharmacological treatment for insomnia of any type within the past 6 months,
glaucoma, severe respiratory insufficiency, seizure disorder, or if in the past three
months they have taken any medications that affect sleep, or are currently taking any
regularly dosed prescription medication or any prn medication that is used on average
more than 1x/week
- evidence of chronic sleep disorder including sleep apnea, narcolepsy, periodic limb
movement disorder, restless leg syndrome as determined by medical history, Sleep
Disorders Questionnaire(Douglass, 1994), or by polysomnography (following enrollment)
- current dependence on any drugs other than cocaine or nicotine or lifetime dependence
on alcohol, benzodiazepines, or opiates, or any non-substance related Axis I disorder
as determined by SCID
- current use of alcohol in excess of 3x/week AND 21 standard drinks/week in the past
month or non-zero breathalyzer at screening or study start
- current use of cannabis in the past month
- positive urine toxicology test for opiates, methadone, amphetamines, barbiturates,
benzodiazepines, PCP, methaquolone, and propoxyphene at the time of screening or
positive test for any of those listed plus cannabis at the time of study start
- pregnancy as determined by serum β-HCG at screening or lactating per report
- females: unwillingness to use barrier contraceptives during sexual intercourse for
the duration of the study
- known hypersensitivity to modafinil.
Locations and Contacts
Erica Forselius, B.A., Phone: 203-974-7545, Email: erica.forselius@yale.edu
Connecticut Mental Health Center, New Haven, Connecticut 06519, United States; Recruiting
Additional Information
Starting date: April 2010
Last updated: January 21, 2015
|